Celularity, Inc.

As of September 2, 2025, Celularity, Inc. shows a mildly bullish trend with mixed signals from MACD and bearish Bollinger Bands, while underperforming the S&P 500 significantly over the past three years.

As of August 14, 2023, Celularity, Inc. is considered risky due to its overvaluation indicated by a Price to Book Value of 5.64 and an EV to Sales ratio of 1.69, alongside significant operational losses and poor stock performance, contrasting sharply with its peers.

As of August 14, 2023, Celularity, Inc. is considered overvalued and risky due to troubling financial ratios, including a Price to Book Value of 5.64 and negative earnings metrics, alongside significant underperformance compared to the S&P 500.

As of May 1, 2025, Celularity, Inc. shows a mildly bearish trend due to conflicting signals from moving averages and indicators, suggesting caution despite some potential for recovery.

Celularity, Inc. is a blank check company focused on business combinations in the miscellaneous industry, with a market cap of $41.67 million. As of December 2024, it reported net sales of $18 million and a net loss of $13 million.

As of Jun 18, Celularity, Inc. has a market capitalization of 41.67 million, with net sales of 54.22 million and a net profit of -57.89 million over the last four quarters. Shareholder's funds are 8.84 million, and total assets are 314.09 million.